跳至主要内容
临床试验/JPRN-jRCT1051210147
JPRN-jRCT1051210147招募中3 期

A Randomized Controlled Trial of the Preventive Effect of Haptoglobin Administration on Hemolysis-Related Organ Damage in Patients undergoing Cardiovascular Surgery

Hokka Mai0 个研究点目标入组 140 人开始时间: 2022年1月5日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1.Patients who undergo cardiovascular surgery required cardiopulmpnary bypass
  • 2.Patients aged 20 years or older
  • 3.Patients who have given written consent to participate in this study
  • 4.Patients with a free hemoglobin concentration of more than 50 mg/dL within 2 hours of starting cardiopulmonary bypass

排除标准

  • 1.Patients who had already had renal replacemt therapy
  • 2.Patients with a preoperative serum creatinine level of 2 mg/dl or higher
  • 3.Patients scheduled for surgery involving the descending aorta
  • 4.Patients who undergoing MICS (Minimum Invasive Cardiac Surgery)
  • 5.Patients with haptoglobin deficiency
  • 6.Patients with IgA deficiency
  • 7.Patients with hepatic impairment(Bil>2.0mg/dL)
  • 8.Patients with hemolytic diseases(Autoimmune haemolytic anaemia, paroxysmal nocturnal haemoglobinuria, hereditary spherocytosis, etc.)
  • 9.Immunocompromised and immunosuppressed patients(e.g. patients on immunosuppressive drugs or who have used chemotherapeutic drugs for malignancy within the last year)
  • 10.Patients who are deemed inappropriate by the study investigators

研究者

发起方
Hokka Mai

相似试验